VRTX Vertex Pharmaceuticals
- 464.920
- -12.980-2.72%
- 465.000
- +0.080+0.02%
Vertex Pharmaceuticals News
The Best Biotech Plays Outside the GLP-1 Weight-loss Market
Express News | RBC Capital Reiterates Sector Perform on Vertex Pharmaceuticals, Maintains $431 Price Target
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals (VRTX) Gets a Hold From RBC Capital
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
What Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) P/S Is Not Telling You
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Vertex Pharmaceuticals, Inc. (VRTX) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
'Trump Trade' vs. 'Harris Trade': How They Could Shape Your Portfolio
Vertex Pharmaceuticals Incorporated (VRTX) Is Attracting Investor Attention: Here Is What You Should Know
Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?
Vertex Pharmaceutical Inc. (VRTX): Jim Cramer's Go-To Stock For Success
Vertex Pharmaceuticals Hits 4-week High
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Are Wall Street Analysts Bullish on Vertex Pharmaceuticals Stock?
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Analysis
Price Target
No Data
No Data
